As the global voice of the Advanced Therapy Medicinal Product (ATMP) sector, the Alliance for Regenerative Medicine (ARM) welcomes the European Commissions ambition to strengthen the EUs pharmaceutical framework to ensure it meets the needs of patients in Europe and creates a conducive environment for the development of innovative medicines.
ARM
Alliance for Regenerative Medicine
Other · Belgium · EU Transparency Register 244710319190-73
7
positions filed
in the 665 files tracked
5
legislative files
of 665 tracked
6
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1106 non-governmental organisations on this site, they rank #243 by legislative files engaged, a count of participation, not a measure of influence.
1
declared lobbying FTE
self-declared
€400K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
- Standards Coordinating Body for Gene, Cell and Regenerative Medicines and Cell-Based Drug Discovery
- Foundation for Cell and Gene Medicine
- National Academy of Sciences Forum on Regenerative Medicine
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Non-governmental organisations
- Head office
- Washington DC, United states
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Alliance in PolicySpeak: request access →
Work at Alliance for Regenerative Medicine? so we know who speaks for it.
Their record over time
Alliance for Regenerative Medicine filed 7 positions between 14 Dec 2020 and 10 Jun 2025, across 5 of the 665 legislative files tracked here, attaching a full position paper 6 times.
2020 · 1 filed2021 · 3 filed2022 · 1 filed2023 · 1 filed2025 · 1 filed
What they argued
ARM welcomes the review of the general Pharma legislation and the Commission’s objectives of enabling innovation, reducing the regulatory burden, whilst ensuring high quality and safety standards for pharmaceuticals.
The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organisation representing the advanced therapy medicinal products sector, which includes cell and gene therapies and tissue-engineered products. ARMs membership includes more than 400 organisations, ranging from small and medium-sized enterprises and large companies to academic institutions and non-profit research centres.
The Alliance for Regenerative Medicine (ARM, www.alliancerm.org) is the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs). ARM promotes legislative, regulatory and reimbursement initiatives in Europe and internationally to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based…
The Alliance for Regenerative Medicine (ARM) welcomes the European Commission’s efforts to update and harmonise the standards of quality and safety for substances of human origin (SoHO) and the choice of a Regulation as the legal instrument for this. The proposed Regulation is of great relevance to ATMP developers because SoHO are most often used as starting materials for ATMPs.
The Alliance for Regenerative Medicines (ARM) thanks the European Commission for providing insights on its plan for addressing gaps and shortcomings in the current Blood, Tissues and Cells (BTC) legislation and welcomes the European Commission (EC)'s objectives to ensure safety and quality for patients and to support innovation.
As the leading international advocacy organisation dedicated to realizing the promise of advanced therapy medicinal products (ATMPs) and the global voice of the sector, the Alliance for Regenerative Medicine (ARM) welcomes the opportunity to provide feedback on this inception impact assessment.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Alliance for Regenerative Medicine next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 126.
Is this your organization?
Everything on this page comes from Alliance for Regenerative Medicine’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.